| Title |
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
|
|---|---|
| Published in |
AMB Express, April 2016
|
| DOI | 10.1186/s13568-016-0201-4 |
| Pubmed ID | |
| Authors |
Aifen Li, Jieyu Xing, Li Li, Changhua Zhou, Bin Dong, Ping He, Qing Li, Zhong Wang |
| Abstract |
Her2, which is frequently overexpressed in breast cancer, is one of the most studied tumor-associated antigens for cancer therapy. Anti-HER2 monoclonal antibody, trastuzumab, has achieved significant clinical benefits in metastatic breast cancer. In this study, we describe a novel bispecific antibody Her2-S-Fab targeting Her2 by linking a single domain anti-CD16 VHH to the trastuzumab Fab. The Her2-S-Fab antibody can be efficiently expressed and purified from Escherichia coli, and drive potent cancer cell killing in HER2-overexpressing cancer cells. In xenograft model, the Her2-S-Fab suppresses tumor growth in the presence of human immune cells. Our results suggest that the bispecific Her2-S-Fab may provide a valid alternative to Her2 positive cancer therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 2% |
| Unknown | 44 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 24% |
| Student > Ph. D. Student | 9 | 20% |
| Student > Bachelor | 7 | 16% |
| Student > Master | 4 | 9% |
| Other | 2 | 4% |
| Other | 5 | 11% |
| Unknown | 7 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 12 | 27% |
| Agricultural and Biological Sciences | 8 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Medicine and Dentistry | 3 | 7% |
| Engineering | 3 | 7% |
| Other | 8 | 18% |
| Unknown | 7 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#4,519,486
of 22,818,766 outputs
Outputs from AMB Express
#92
of 1,234 outputs
Outputs of similar age
#71,405
of 298,806 outputs
Outputs of similar age from AMB Express
#4
of 20 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,234 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,806 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.